Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent